Anticoagulant effects of Trasylol: in vitro and in vivo studies.
D000037:Abruptio Placentae / Q000188:drug therapy; D000328:Adult; D007611:Aprotinin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000032:analysis; D005165:Factor V / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005898:Glass; D006470:Hemorrhage / Q000188:drug therapy; D006474:Hemorrhagic Disorders / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis; D011183:Postoperative Complications / Q000188:drug therapy; D011247:Pregnancy; D011516:Prothrombin / Q000032:analysis; D013917:Thrombin / Q000032:analysis; D013925:Thromboplastin / Q000494:pharmacology; D013997:Time Factors
D005165:Factor V; D011516:Prothrombin; D005169:Factor VIII; D005340:Fibrinogen; D010958:Plasminogen; D013925:Thromboplastin; D007611:Aprotinin; D013917:Thrombin